Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up to $37.88

Structure Therapeutics Inc. (NASDAQ:GPCR)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $37.88, but opened at $38.93. Structure Therapeutics shares last traded at $37.96, with a volume of 59,846 shares changing hands.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of Structure Therapeutics in a research report on Tuesday, May 21st. They issued an “overweight” rating and a $65.00 target price for the company. BMO Capital Markets lifted their price target on shares of Structure Therapeutics from $83.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, June 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a report on Monday, June 17th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a report on Friday, May 10th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $85.25.

Structure Therapeutics Stock Performance

The stock has a market capitalization of $1.83 billion and a P/E ratio of -51.00. The stock’s fifty day simple moving average is $41.59 and its two-hundred day simple moving average is $41.74.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, May 9th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. As a group, analysts expect that Structure Therapeutics Inc. will post -0.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Brandywine Managers LLC grew its holdings in Structure Therapeutics by 9.2% during the 4th quarter. Brandywine Managers LLC now owns 12,007 shares of the company’s stock worth $489,000 after acquiring an additional 1,007 shares during the last quarter. Teachers Retirement System of The State of Kentucky grew its holdings in Structure Therapeutics by 17.8% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 13,733 shares of the company’s stock worth $589,000 after acquiring an additional 2,077 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Structure Therapeutics by 208.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,349 shares of the company’s stock valued at $177,000 after purchasing an additional 2,939 shares during the last quarter. Sectoral Asset Management Inc. bought a new stake in shares of Structure Therapeutics in the 4th quarter valued at $139,000. Finally, TrueMark Investments LLC boosted its stake in shares of Structure Therapeutics by 13.5% in the 1st quarter. TrueMark Investments LLC now owns 29,884 shares of the company’s stock valued at $1,281,000 after purchasing an additional 3,562 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.